Hao Xu

Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.

Drugs for aging-related diseases may modulate aging itself, but standard clinical trial designs cannot detect such effects. Aging clocks could close this gap, but epigenetic models often yield inconsistent, hard-to-interpret results. In contrast, proteomic clocks, by tracking the immediate effectors of biological chang...